US EditionPublished • loading... • Updated
Extended-Release Buprenorphine Linked to Higher Opioid Abstinence in Pregnancy Than Daily Treatment
Summary by APF
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Extended-Release Buprenorphine Linked to Higher Opioid Abstinence in Pregnancy Than Daily Treatment
A randomized clinical trial published in JAMA Internal Medicine found that weekly extended-release buprenorphine during pregnancy was associated with higher rates of abstinence from illicit opioids than daily sublingual buprenorphine among pregnant women with opioid use disorder. Overall maternal and infant outcomes were similar between groups. However, the extended-release buprenorphine group reported fewer serious adverse events, less use of p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
